Testing CBP-0276 for moderate to severe psoriasis
Part of Skin clinical trials.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had stable plaque psoriasis for at least 6 months.
- Your psoriasis covers 10% or more of your body (like the size of your palms).
- You are between 18 and 70 years old.
- You have not used certain psoriasis treatments (like phototherapy or strong creams) recently.
- You are willing to use effective birth control if needed.
- You have no active infections, recent serious infections, or untreated tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication (HS-10374) taken by mouth to see if it is safe and effective for people with moderate to severe plaque psoriasis. It might help reduce the redness, scaling, and thickness of psoriasis plaques.
This trial tests a new study drug called HSK44459 for people with moderate to severe plaque psoriasis. The hope is that the drug can reduce psoriasis symptoms and improve quality of life. Participation involves receiving the study drug and being monitored for safety and effectiveness.
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
This study tests a new injection called SHR-1139 for people with moderate-to-severe plaque psoriasis. The goal is to see if it can safely improve your skin condition.
This trial tests an experimental pill that may help clear psoriasis plaques. It is for people whose current topical treatments (creams or ointments) are not working well enough or cause side effects.
This study tests an oral investigational pill (CBP-0276) called an oral therapy for psoriatic arthritis. The goal is to see if it reduces joint pain, swelling, and psoriasis symptoms better than a placebo (inactive pill).
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.